Case number# PHHY2015ES060055, is an initial spontaneous report from a physician received via pharmaceutical 
company Biogen on 15 May 2015. 
This report refers to a 32-year-old female patient. Medical history was not reported. No concomitant medication was
reported. The patient was on Tysabri (natalizumab) before Gilenya, as the case was received from Biogen.
The patient received Gilenya (fingolimod) capsule for an unspecified indication, date, dosage and route of 
administration.
In Apr 2015, the patient experienced suspicion of PML (progressive multifocal leukoencephalopathy). Action taken 
with Gilenya was unknown.
Seriousness, causality and outcome of the event were not reported. Seriousness assessment of the event 
Print Time: 07-JUN-2016 03:01 PM If a field is blank, there is no data for that field Page 464 of 549
FDA - Adverse Event Reporting System (FAERS) 
FOIA Case Report Information
progressive multifocal leukoencephalopathy was upgraded based on the NVS-IME list. 
The company currently did not have the contact details of reporting physician from Biogen. It was in contact with 
Biogen to get the contact details of reporting physician, and would follow-up on the case accordingly.